Cleveland HeartLab

Cleveland HeartLab is involved in the discovery and validation of molecular biomarkers and their development into products that aid in the diagnosis and treatment of a variety of diseases. The initial focus is on Myeloperoxidase (MPO), a diagnostic marker of cardiovascular risk, and the company has received 510(k) clearance to market its first biomarker, CardioMPO.

Funding: HealthCare Ventures, Excel Venture Management, Glengary Ventures, Zapis Capital, Second Generation, Mutual Capital Partners, Bratenahl Capital Partners, Merck Global Health Innovation, Angel Investor, Advantage Capital Partners

Stage: Commercial

News: Cleveland HeartLab Acquired by Quest Diagnostics,Cleveland HeartLab Adds Two Patents for the Myeloperoxidase Test